ストックスクリーナーアプリを入手
5.35
0.37%
0.010
前日終値:
$5.34
開ける：
$5.34
24時間の取引高:
6,806
Relative Volume:
0.12
時価総額：
$166.27M
収益：
-
当期純損益:
$-69.00M
株価収益率:
-1.9245
EPS:
-2.78
ネットキャッシュフロー:
$-55.26M
1週間 パフォーマンス:
-3.25%
1か月 パフォーマンス:
-3.42%
6か月 パフォーマンス:
-42.18%
1年 パフォーマンス:
+19.91%
1日の値動き範囲:
$5.25
$5.5899
1週間の範囲:
$5.25
$5.96
52週間の値動き範囲:
$4.31
$11.90
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
名前
Acrivon Therapeutics Inc
セクター
電話
617-207-8979
住所
480 ARSENAL WAY, SUITE 100, WATERTOWN
ACRV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
5.33 | 166.27M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.82 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.33 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
625.06 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
247.94 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
270.65 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-31 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-12-15 | 再開されました | Jefferies | Buy |
| 2023-10-05 | 開始されました | Maxim Group | Buy |
| 2023-06-02 | 開始されました | Oppenheimer | Outperform |
| 2023-05-08 | 開始されました | BMO Capital Markets | Outperform |
| 2023-04-27 | 開始されました | Ladenburg Thalmann | Buy |
| 2023-04-20 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-12 | 開始されました | Cowen | Outperform |
| 2022-12-12 | 開始されました | Jefferies | Buy |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Acrivon Therapeutics Inc (ACRV) 最新ニュース
When (ACRV) Moves Investors should Listen - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Average Target Price from Analysts - Defense World
We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely - Yahoo Finance
(ACRV) Trading Signals - Stock Traders Daily
Brokers Set Expectations for ACRV FY2024 Earnings - MarketBeat
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay - MSN
Acrivon Therapeutics Inc (ACRV) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Acrivon Therapeutics announces FDA granted BDD for ACR-368 - Yahoo Finance
Research Analysts Offer Predictions for ACRV FY2024 Earnings - Defense World
The -10.05% Simple Moving Average of Acrivon Therapeutics Inc’s (ACRV) Stock in the Past 200 Days - The News Heater
Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status - Insider Monkey
Acrivon Therapeutics Announces FDA has Granted Breakthrough - GlobeNewswire
ACR-368 OncoSignature assay gains FDA breakthrough status - MSN
12 AI News and Ratings Investors are Keeping Their Eye On - Insider Monkey
Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer - MSN
Acrivon Therapeutics Says FDA Grants its ACR-368 OncoSignature Assay Breakthrough Device Designation - Marketscreener.com
Acrivon Therapeutics, Inc. Announces FDA Grants Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - Marketscreener.com
Acrivon Therapeutics Gets FDA Breakthrough Device Designation for Cancer Identification - Marketscreener.com
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times
ACR-368 OncoSignature assay gains FDA breakthrough status By Investing.com - Investing.com UK
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 - The Bakersfield Californian
Acrivon's AI-Powered Cancer Test Achieves 62.5% Response Rate, Earns FDA Breakthrough Status - StockTitan
Acrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated at KeyCorp - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Research Coverage Started at Cantor Fitzgerald - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) Earns Overweight Rating from Analysts at KeyCorp - Defense World
Head-To-Head Analysis: Jazz Pharmaceuticals (NASDAQ:JAZZ) & Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Rises By 6.3% - MarketBeat
JPMorgan Chase & Co. Has $238,000 Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Cantor Fitzgerald sets Acrivon stock to Overweight on AP3 platform - MSN
Cantor Fitzgerald Initiates Acrivon Therapeutics at Overweight -January 31, 2025 at 08:14 am EST - Marketscreener.com
(ACRV) Trading Report - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Average PT from Brokerages - Defense World
Barclays PLC Raises Stock Holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 6.3% in December - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
(ACRV) On The My Stocks Page - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Significant Growth in Short Interest - MarketBeat
Geode Capital Management LLC Has $2.12 Million Stake in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
(ACRV) Investment Report - Stock Traders Daily
Barclays PLC Acquires 11,273 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
State Street Corp Acquires 47,233 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Consensus PT from Brokerages - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Charles Schwab Investment Management Inc. Sells 27,705 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
(ACRV) Long Term Investment Analysis - Stock Traders Daily
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha
Acrivon Therapeutics Inc (ACRV) 財務データ
収益
当期純利益
現金流量
EPS
Acrivon Therapeutics Inc (ACRV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 11 '24 |
Buy |
8.50 |
2,353,000 |
20,000,500 |
5,360,858 |
2.61%
0.40%
大文字化:
|
ボリューム (24 時間):